Change over period: —
NSE · NEPHROPLUS
NEPHROPLUS
-14.7% from the 52-week high · +45.4% above the low
Nephrocare Health Services Ltd specializes in renal care and dialysis services. The company operates dialysis centers offering treatment to patients with chronic kidney disease. It follows a standardized care delivery model focused on clinical protocols and patient outcomes. Nephrocare collaborates with hospitals and healthcare institutions to expand access. Its operations are centered on affordable, long-term disease management.
The short version. Return on equity was 6.9% in Mar 2026. Promoter holding was 58.31% in Sep 2026, down 5.54 points over 4 quarters.
1 · The price
How has the stock traded?
NEPHROPLUS trades 14.7% below its 52-week high and 45.4% above its 52-week low.
2 · The business
Is it growing?
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | 303 | 282 | 266 | 260 |
| Net profit | 34 | 32 | 30 | 32 |
| Net margin % | 11.1 | 11.3 | 11.4 | 12.4 |
| EPS (₹) | 3.33 | 3.19 | 3.03 | 3.21 |
Annual
| FY2026 | |
|---|---|
| Revenue | 999 |
| Net profit | 77 |
| Net margin % | 7.7 |
| EPS (₹) | 7.66 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 6.9% in Mar 2026; debt to equity is 0.07.
Profitability · 1 years
Returns and margins
| Mar 2026 | |
|---|---|
| Return on equity % | 6.9 |
| Return on capital % | 13.7 |
| EBITDA margin % | 24.6 |
| Net margin % | 7.5 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | — | — |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Down 5.54 pts over 4 quarters.
Up 2.43 pts over 4 quarters.
Up 0.01 pts over 4 quarters.
+4 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|
| Promoter | 63.85 | 63.85 | 63.85 | 58.31 | -5.54 |
| FII | 9.3 | 9.94 | 8.78 | 11.73 | +2.43 |
| DII | 8.1 | 8.65 | 9.05 | 8.11 | +0.01 |
| Public | 18.74 | 17.56 | 18.32 | 21.85 | +3.11 |
Mutual fund holdings · Oct 2026
27 schemes hold this stock
23 the month before.
- LIC MF HEALTHCARE FUND4.14% of NAV
- LIC MF VALUE FUND4.11% of NAV
- LIC MF INFRASTRUCTURE FUND2.24% of NAV
- Baroda BNP Paribas Health and Wellness Fund1.35% of NAV
- LIC MF MULTI ASSET ALLOCATION FUND1.33% of NAV
- Helios Small Cap Fund1.24% of NAV
- DSP Healthcare Fund1.05% of NAV
- SBI Healthcare Opportunities Fund1.01% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for NEPHROPLUS are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Healthcare Services stocks
Quick answers
Common questions about NEPHROPLUS
What is the NEPHROPLUS share price?
NEPHROPLUS (NEPHROPLUS) last closed at ₹641.95, down 1.69% on the day. Its 52-week range is ₹449.15 to ₹765.35.
What is the market cap of NEPHROPLUS?
NEPHROPLUS has a market capitalisation of about ₹6,558 crore. Its price-to-earnings ratio is 51.4.
How are NEPHROPLUS's latest results?
Return on equity was 6.9% in Mar 2026. Promoter holding was 58.31% in Sep 2026, down 5.54 points over 4 quarters.
Who owns NEPHROPLUS?
As of Sep 2026, shareholding was: Promoter 58.31%, FII 11.73%, DII 8.11%, Public 21.85%.
How many mutual funds hold NEPHROPLUS?
27 mutual fund schemes held NEPHROPLUS in October 2026. That compares with 23 the month before.
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.